Meeder Asset Management’s Checkpoint Therapeutics CKPT Stock Holding History

Meeder Asset Management’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-96	Closed	-$2K	–	2203
2022 Q1	$2K	Buy	+96	New	+$2.06K	﹤0.01%	2019
2021 Q4	–	Sell	-92	Closed	-$3K	–	1376
2021 Q3	$3K	Hold	92	–	–	﹤0.01%	2062
2021 Q2	$3K	Hold	92	–	–	﹤0.01%	2084
2021 Q1	$3K	Buy	+92	New	+$3.08K	﹤0.01%	1968
2020 Q4	–	Sell	-92	Closed	-$2K	–	1925
2020 Q3	$2K	Hold	92	–	–	﹤0.01%	1818
2020 Q2	$2K	Hold	92	–	–	﹤0.01%	1751
2020 Q1	$1K	Buy	+92	New	+$1.63K	﹤0.01%	2170
2019 Q4	–	Sell	-69	Closed	-$2K	–	2267
2019 Q3	$2K	Buy	+69	New	+$1.89K	﹤0.01%	1938

Other funds holding CKPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Meeder Asset Management's CKPT Position: Q2 2022 in Review

Meeder Asset Management sold out of Checkpoint Therapeutics (CKPT) in Q2 2022, closing a stake of 96 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in CKPT in Q3 2019 and held it in 8 quarters. The position peaked at $3K in Q3 2021. 62 funds tracked by Wall St. Rank hold CKPT as of Q2 2022.

Meeder Asset Management reported no remaining Checkpoint Therapeutics position as of Q2 2022 after selling out during the quarter.
Meeder Asset Management sold 96 Checkpoint Therapeutics shares in Q2 2022, an estimated $2K.
Meeder Asset Management first reported a position in Checkpoint Therapeutics in Q3 2019 and held it in 8 quarters.
Meeder Asset Management's Checkpoint Therapeutics position peaked at $3K in Q3 2021.
62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2022.

Based on Meeder Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.